focus -WSS

focus

author：knowledge 2025-09-29 23:03:51 - browse：99

The back of three medicine containers, a bottle in between two boxes, all showing labels — coverage from STAT — Adobe

After a drug enters the market, it’s up to Food and Drug Administration regulators to ensure its continued safety and efficacy. A recent New York Times story suggests that, in the case of the popular asthma drug Singulair, the FDA fell short — both because the agency delayed action for years on reports from patient advocates and independent groups that the drug could cause suicidal thoughts, and because when it did add a warning label about its potential side effects in 2020, clinicians and patients still weren’t always aware of the risks.

Experts say that the Singulair incident highlights a flawed system, both in the U.S. and globally, for monitoring adverse reactions after a drug is on the market — one that will require extensive changes to address.

“The question is, how safe do you want to be?” said Ameet Sarpatwari, the assistant director of the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital. Ideally, he said, the FDA should be able to both stay on top of safety concerns and avoid unnecessarily restricting access to drugs. “Are we at the right balance? I think there are definitely situations for many drugs where you can say, no, we’re not really at the right balance, and the FDA should be taking a more aggressive stance in promoting patient safety.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Why the drug industry's warnings on the IRA's impact fall short

Wikipedia

WSS

Assistant physicians can help address the primary care shortage

Medicare threatens to cut off funding for HCA's Mission hospital

To avoid data mishandling cases, universities eye AI and other tools

'A game

Gilead might be held responsible for not developing a drug

How digital tools helped lower hypertension in marginalized patients

explore

focus

hotspot

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Medical mystery: When a cough is not just a cough

New air purifier tech could be key to improving indoor air quality

What happened to the House vote on health price transparency?

Virginia high school admissions case could be legal follow

For Medicare Advantage, Democrats want stronger protections around AI

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The Readout: Gilead, Bernie Sanders, and other pharma news

Psychedelics group wrestles with new pharma identity

Free Covid tests will again be offered to all U.S. households

knowledge

Medicare threatens to cut off funding for HCA's Mission hospital

Vaccine advisory panel ACIP left half staffed by HHS

Chamber of Commerce, DOJ clash in court over drug prices

Why did Pfizer dish out millions for a Super Bowl ad?

Fed up with FDA, ALS advocates consider a take

Akili changes sales model for its ADHD video game treatment

Wikipedia

hotspot

focus

knowledge